Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.
XELJANZ (tofacitinib citrate) is the first JAK inhibitor licensed for use in the treatment of Rheumatoid Arthritis (RA), Ulcerative Colitis (UC) and Psoriatic Arthritis (PsA).1
Please select the most relevant therapeutic area below for dedicated resources and information relating to the efficacy, safety and usage of XELJANZ.
Find the information you need to support your RA patient here.
Visit RA Efficacy
Find the information you need to support your PsA patient here.
Visit PsA Efficacy
Find the information you need to support your UC patient here.
Visit UC Efficacy
If you are new to XELJANZ, this short video contains useful information on how XELJANZ works.
Mode of action
Please click here for an overview of the safety profile of XELJANZ across all licensed indications.
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020